Creative Commons source reading · Headache and migraine
P2Y12 receptor mediates microglial activation via RhoA/ROCK pathway in the trigeminal nucleus caudalis in a mouse model of chronic migraine.
Feng Jing; Yixin Zhang; Ting Long; Wei He; Guangcheng Qin; Dunke Zhang; Lixue Chen; Jiying Zhou
Originally published in Journal of neuroinflammation · 2019-11-13
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background Microglial activation contributes to the development of chronic migraine (CM). The P2Y12 receptor (P2Y12R), a metabolic purinoceptor that is expressed on microglia in the central nervous system (CNS), has been indicated to play a critical role in the pathogenesis of chronic pain. However, whether it contributes to the mechanism of CM remains unknown. Thus, the present study investigated the precise details of microglial P2Y12R involvement in CM. Methods Mice subjected to recurrent nitroglycerin (NTG) treatment were used as the CM model. Hyperalgesia were assessed by mechanical withdrawal threshold to electronic von Frey and thermal withdrawal latency to radiant heat. Western blot and immunohistochemical analyses were employed to detect the expression of P2Y12R, Iba-1, RhoA, and ROCK2 in the trigeminal nucleus caudalis (TNC). To confirm the role of P2Y12R and RhoA/ROCK in CM, we systemically administered P2Y12R antagonists (MRS2395 and clopidogrel) and a ROCK2 inhibitor (fasudil) and investigated their effects on microglial activation, c-fos, and calcitonin gene-related peptide (CGRP) expression in the TNC.
Discussion
We found the following new results in the present study. First, using an animal model of chronic NTG treatment-induced CM, we provided the first evidence that microglial P2Y12R in the TNC participates in the pathogenesis of CM. Then, we showed that microglial P2Y12R regulated activated microglial morphological changes and inflammatory factor production in the TNC via the RhoA/ROCK pathway during CM. Finally, we presented the first evidence that the RhoA/ROCK2 pathway contributes to the development of CM.
Conclusion
In conclusion, we demonstrated the roles of microglial P2Y12R in the TNC in CM. These roles include affecting microglial morphological changes and inflammatory factor production in the TNC through the RhoA/ROCK pathway and suppressing the expression of CGRP and c-fos in the TNC. These results suggest a new mechanism of CM and help identify that P2Y12R antagonists, such as clopidogrel, might be a new therapeutic strategy for treating CM in the clinic.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
